Mike Nally, Generate Biomedicines CEO
Amgen partners with Flagship's machine learning startup, promising up to $1.9B as Big Pharma ups bet on AI
Amgen is approaching the new year the same way it tackled 2021: swinging deals. But now it’s aiming to bring AI capabilities into the fold …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
